Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Image

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

Article Created on 24 Aug 2026 by GSK News Feed

If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement